Retinoid_NN
X_NN
receptor_NN
-LRB-_-LRB-
RXR_NN
-RRB-_-RRB-
agonist-induced_JJ
activation_NN
of_IN
dominant-negative_JJ
RXR-retinoic_JJ
acid_NN
receptor_NN
alpha403_NN
heterodimers_NNS
is_VBZ
developmentally_RB
regulated_VBN
during_IN
myeloid_JJ
differentiation_NN
._.

The_DT
multiple_JJ
biologic_JJ
activities_NNS
of_IN
retinoic_JJ
acid_NN
-LRB-_-LRB-
RA_NN
-RRB-_-RRB-
are_VBP
mediated_VBN
through_IN
RAR_NN
and_CC
retinoid_NN
X_NN
receptor_NN
-LRB-_-LRB-
RXR_NN
-RRB-_-RRB-
nuclear_JJ
receptors_NNS
that_WDT
interact_VBP
with_IN
specific_JJ
DNA_NN
target_NN
sequences_NNS
as_IN
heterodimers_NNS
-LRB-_-LRB-
RXR-RAR_NN
-RRB-_-RRB-
or_CC
homodimers_NNS
-LRB-_-LRB-
RXR-RXR_NN
-RRB-_-RRB-
._.

RA_NN
receptor_NN
activation_NN
appears_VBZ
critical_JJ
to_TO
regulating_VBG
important_JJ
aspects_NNS
of_IN
hematopoiesis_NN
,_,
since_IN
transducing_VBG
a_DT
COOH-terminally_RB
truncated_VBN
RARalpha_NN
exhibiting_VBG
dominant-negative_JJ
activity_NN
-LRB-_-LRB-
RARalpha403_NN
-RRB-_-RRB-
into_IN
normal_JJ
mouse_NN
bone_NN
marrow_NN
generates_VBZ
hematopoietic_JJ
growth_NN
factor-dependent_JJ
cell_NN
lines_NNS
frozen_VBN
at_IN
the_DT
multipotent_JJ
progenitor_NN
-LRB-_-LRB-
EML_NN
-RRB-_-RRB-
or_CC
committed_VBN
promyelocyte_JJ
-LRB-_-LRB-
MPRO_NN
-RRB-_-RRB-
stages_NNS
._.

Nevertheless_RB
,_,
relatively_RB
high_JJ
,_,
pharmacological_JJ
concentrations_NNS
of_IN
RA_NN
-LRB-_-LRB-
1_CD
to_TO
10_CD
&_NN
mgr_NN
;_:
M_NN
-RRB-_-RRB-
overcome_VBP
these_DT
differentiation_NN
blocks_NNS
and_CC
induce_VBP
terminal_JJ
granulocytic_JJ
differentiation_NN
of_IN
the_DT
MPRO_NN
promyelocytes_NNS
while_IN
potentiating_NN
interleukin-3_NN
-LRB-_-LRB-
IL-3_NN
-RRB-_-RRB-
-_:
induced_VBN
commitment_NN
of_IN
EML_NN
cells_NNS
to_TO
the_DT
granulocyte\/monocyte_NN
lineage_NN
._.

In_IN
the_DT
present_JJ
study_NN
,_,
we_PRP
utilized_VBD
RXR_NN
-_:
and_CC
RAR-specific_JJ
agonists_NNS
and_CC
antagonists_NNS
to_TO
determine_VB
how_WRB
RA_NN
overcomes_VBZ
the_DT
dominant-negative_JJ
activity_NN
of_IN
the_DT
truncated_VBN
RARalpha_NN
in_IN
these_DT
different_JJ
myeloid_JJ
developmental_JJ
stages_NNS
._.

Unexpectedly_RB
,_,
we_PRP
observed_VBD
that_IN
an_DT
RXR-specific_JJ
,_,
rather_RB
than_IN
an_DT
RAR-specific_JJ
,_,
agonist_NN
induces_VBZ
terminal_JJ
granulocytic_JJ
differentiation_NN
of_IN
MPRO_NN
promyelocytes_NNS
,_,
and_CC
this_DT
differentiation_NN
is_VBZ
associated_VBN
with_IN
activation_NN
of_IN
DNA_NN
response_NN
elements_NNS
corresponding_VBG
to_TO
RAR-RXR_JJ
heterodimers_NNS
rather_RB
than_IN
RXR-RXR_JJ
homodimers_NNS
._.

This_DT
RXR_NN
agonist_NN
activity_NN
is_VBZ
blocked_VBN
by_IN
RAR-specific_JJ
antagonists_NNS
,_,
suggesting_VBG
extensive_JJ
cross-talk_NN
between_IN
the_DT
partners_NNS
of_IN
the_DT
RXR-RARalpha403_NN
heterodimer_NN
._.

In_IN
contrast_NN
,_,
in_IN
the_DT
more_RBR
immature_JJ
,_,
multipotent_JJ
EML_NN
cells_NNS
we_PRP
observed_VBD
that_IN
this_DT
RXR-specific_JJ
agonist_NN
is_VBZ
inactive_JJ
either_CC
in_IN
potentiating_VBG
IL-3-mediated_JJ
commitment_NN
of_IN
EML_NN
cells_NNS
to_TO
the_DT
granulocyte_NN
lineage_NN
or_CC
in_IN
transactivating_VBG
RAR-RXR_JJ
response_NN
elements_NNS
._.

RA-triggered_JJ
GALdbd-RARalpha_NN
hybrid_NN
activity_NN
in_IN
these_DT
cells_NNS
indicates_VBZ
that_IN
the_DT
multipotent_JJ
EML_NN
cells_NNS
harbor_VBP
substantial_JJ
nuclear_JJ
hormone_NN
receptor_NN
coactivator_NN
activity_NN
._.

However_RB
,_,
the_DT
histone_NN
deacetylase_NN
-LRB-_-LRB-
HDAC_NN
-RRB-_-RRB-
inhibitor_NN
trichostatin_NN
A_NN
readily_RB
activates_VBZ
an_DT
RXR-RAR_NN
reporter_NN
construct_NN
in_IN
the_DT
multipotent_JJ
EML_NN
cells_NNS
but_CC
not_RB
in_IN
the_DT
committed_VBN
MPRO_NN
promyelocytes_NNS
,_,
indicating_VBG
that_IN
differences_NNS
in_IN
HDAC-containing_JJ
repressor_NN
complexes_NNS
in_IN
these_DT
two_CD
closely_RB
related_JJ
but_CC
distinct_JJ
hematopoietic_JJ
lineages_NNS
might_MD
account_VB
for_IN
the_DT
differential_JJ
activation_NN
of_IN
the_DT
RXR-RARalpha403_NN
heterodimers_NNS
that_IN
we_PRP
observed_VBD
at_IN
these_DT
different_JJ
stages_NNS
of_IN
myeloid_JJ
development_NN
._.

